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 Tropical and subtropical countries are regions with high incidence of dengue 
infection. Dengue virus infection is estimated to cause 300 million new infections in 
one year and approximately 1 million severe cases with 2 + 5% deaths. The case of 
dengue in Indonesia has continued to increase since 1968 until 1980 where all 
provinces in Indonesia have been affected by the dengue virus. Dengue virus is a virus 
carried by the Aedes aegypti mosquito in its salivary gland. The virus which is a 
family group of Flaviviruses has four homologous serotypes, namely DENV-1, 
DENV-2, DENV-3, and DENV-4, which can cause dengue infection in individuals. 
Currently there is a shift in the target population from children to adults. This is a 
problem that needs to be resolved by the government and the community itself. 
Solution to overcome this, the government needs early prevention efforts to reduce 
the severity of dengue infection by developing and researching dengue vaccines. 
Currently a vaccine has been found that can be used as prophylaxis for dengue virus, 
namely Dengvaxia. This vaccine has been recommended by the World Health 
Organization (WHO) as prophylaxis for dengue infection, but Dengvaxia is only used 
in areas that are very endemic to dengue fever. The Indonesian Food and Drug 
Supervisory Agency (BPOM RI) has also approved the use of Dengvaxia as an 
indication of prevention of dengue infection since August 31, 2016. This vaccine has 
been approved globally only given to individuals aged between 9-16 years. 
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INTRODUCTION 
Dengue fever is a disease caused by the bite 
of the Aedes aegypti mosquito carrying dengue 
virus (DENV) in its salivary gland. Dengue is 
found in tropical and subtropical regions 
throughout the world.(1) Estimates that arise due to 
infection from the dengue virus are obtained 
around 300 million new infections per year and 
approximately 1 million cases of serious illness 
with a death of 2 + 5%. The DENV virus presents 
a new challenge for controlling the main mosquito 
vectors, but it is also known that there is no 
effective antiviral to treat DENV infection.(2) At 
present, an efficient prophylactic strategy for 
dengue infection is needed by reviewing the 
epidemiological trends of dengue virus, biology, 
and clinical diseases, which in the next stage are 
expected to help to make efficient vaccine 
strategies.(3) 
 
DENGUE DISEASE 
Epidemiology of dengue 
From 1968 to 2009, the World Health 
Organization (WHO) has noted that Indonesia is 
the country with the highest DHF cases in 
Southeast Asia. Before the DHF case (Dengue 
Hemorrhagic Fever) then spread widely in the 
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territory of Indonesia, this disease first appeared in 
1968 in the city of Surabaya, with a total case of 58 
people infected and 24 other people dying. 
Although it was first discovered in 1968, 
confirmation of a new virological dengue was 
obtained in 1972. In 1980, all provinces in 
Indonesia were affected by dengue and the cases 
continued to increase every year.(4) 
 
Replication of dengue virus 
There are four different types of antigen 
serotypes which are divided homologically by 60-
80%: DENV-1, DENV-2, DENV-3, and DENV-4. 
DENV is a virus particle that is about 50 nm in size 
which is enveloped by a lipid membrane. RNA 
which contains about 11,000 long nucleotide 
frames encodes a large polyprotein and at the post 
translational stage is divided into 3 structural 
proteins such as capsid (C), membrane precursor 
(prM), and envelope (E), and seven non-structural 
proteins such as NS1, NS2a, NS2b , NS3, NS4a, 
NS4b, and NS5. The surface of the virion 
composed of glycoprotein E is used as the main 
target of DENV to neutralize antibodies. The 
ectodomain of E consists of a centrally located I 
(EDI) domain, containing loop fusion II (EDII),and 
domain III which carries almost all antibody-
specific epitope antibodies.(3) 
When genomic RNA is released into the 
cytoplasm and after the fusion of viral membranes 
with endosomal membranes, the translation of viral 
RNA then begins to approach the endoplasmic 
reticulum (RE). After the virus replication complex 
occurs, the translation is stopped, and viral RNA 
synthesis occurs. During the replication process of 
DENV, the viral genome will be degraded by the 
enzyme exonuclease (XRN1) to produce small 
species of subgenomic flavivirus RNA (sfRNAs) 
that are in accordance with the majority of the non-
transplanted genomic region (NTR) at the end of 3 
genomic RNA. The accumulation of sfRNAs 
results in viral replication, but also changes the 
activity of the host cell antivirus to be resistant to 
viral replication. The synthesis of artificial RNA 
molecules contributes to the massive production of 
viral proteins. The RE surface is the assembly 
location of the virus that has not yet matured, the 
virus is carried through the Golgi complex and then 
the PRM is processed into M until it undergoes 
maturation and is ready to be released into 
extracellular.(3) 
 
Symptomatic features of dengue disease 
There are three phases that occur in dengue 
conditions, namely the febrile phase, critical phase, 
and recovery phase. 
1. Febrile phase: dehydration, high fever which 
causes disorders of the nervous system, and 
causes seizures in children. 
2. Critical phase: shock from plasma leakage, 
severe haemorrhage, impairment organs. 
3. Recovery phase: hypervolemia, acute 
pulmonary edema.(1)  
 
HUMAN SUSCEPTIBILITY TO DENGUE 
VIRUS INFECTION 
Currently DHF cases are still considered 
trivial, so it is very easy for every individual who 
lives in an endemic area to be infected with dengue. 
Based on this information, then WHO recommends 
using Dengvaxia Vaccine as a preventive measure. 
The nature of the pathogen DENV has been widely 
reported as infection because DENV-2 is the 
biggest cause of severe dengue compared to other 
serotypes. Clinically the majority of people 
infected with dengue are asymptomatic. According 
to Ten Bosch et., Al., The fastest spread of DENV 
occurs in endemic areas where most are caused by 
an increase in transmission of disease by vectors.(3) 
 
MECHANISM OF DENGUE VACCINE 
The general mechanism of action of the 
dengue vaccine is to stimulate antibody activation 
to be able to fight the four dengue virus serotypes 
measured through PRNT50. After vaccination, titre 
is seen to be higher in seropositive compared to 
seronegative. Furthermore, T cells will be 
stimulated by the presence of foreign structures of 
antigens from the dengue virus and against non-
structural antigens from the YF vaccine virus.(5) 
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DENGUE VACCINE DEVELOPEMENT 
At present, it is known that there are 
vaccines that have passed the clinical phase test 
and are registered as vaccines for the dengue virus. 
This vaccine has been registered in several 
countries in the world, namely the CYD-TDV 
vaccine or Dengvaxia vaccine which is produced 
by a pharmaceutical company in France owned by 
Sanofi Pasteur. Several other candidates besides 
the Dengvaxia vaccine are also starting to be 
developed, but are still in the phase III clinical trial 
phase. The development of vaccines is inseparable 
from the supervision and protection of the World 
Health Oragnization (WHO) regarding the quality, 
safety and effectiveness of the dengue vaccine. The 
CYD-TDV vaccine represented by CYD14 and 
CYD 15 has been evaluated by phase III clinical 
trials using the Randomized Controlled Trials 
(RCT) method in several countries in the world. 
The CYD14 vaccine was evaluated for 10,275 
participants aged 2-14 years in 5 countries in Asia 
in the first vaccination, namely Indonesia, the 
Philippines, Malaysia, Vietnam and Thailand. 
Whereas for CYD15 vaccine, 20,869 participants 
were aged 9-16 years in the first vaccination in 
Latin America, namely Brazil, Colombia, 
Honduras, Mexico, and Puerto Rico. In this 
evaluation, RCT patients were randomized to 
compare vaccines with placebo (0.9% solution of 
sodium chloride) with a ratio of 2: 1. This study 
was carried out for 13 months which was 
calculated from the last dose of vaccination to see 
the primary efficacy endpoint and included 
surveillance data at the Hospital as an additional 
data security for a period of 4 years.(5) 
 
The Efficacy of Vaccine CYD14 and CYD15 
Dengue viruses has been tested and assessed 
based on surveillance data (25 months after being 
registered). This effectiveness test is carried out on 
CYD14 and CYD15 vaccines. Assessments carried 
out on a per protocol basis were based on serotypes, 
namely 56.5% (95% CI 43.8% -66.4%) in CYD14 
and 60.8% (95% CI 52.0% -68.0%) in CYD15 
(from one month post dose 3 for 12 months). 
Furthermore, vaccine effectiveness in fighting 
dengue virus was shown starting from the lowest 
based on serotypes, ie 1 (50.2%, 95% CI 35.6% - 
61.5%), 2 (39.6%, 95% CI 18.7 % -55.2%), 3 
(74.9%, 95% CI 65.1% -82.0%) and 4 (76.6%, 
95% CI 65.0% -84.4.(5) 
In addition to seeing the effectiveness test, it 
is also necessary to find out the results of testing 
the effectiveness of dengue vaccines in several 
countries. The results of the effectiveness tests 
from several countries are quite varied. The 
effectiveness of the dengue vaccine in Mexico 
ranges from 31.3% (95% CI 1.3% -51.9%) and by 
79.0% (95% CI 5.3% -91.5%) in Malaysia.(5) 
This vaccination is carried out at the age of 
9 years and above. Because at the age of <9 years 
and 2-5 years the child's immunity is still low. 
When exposed to this vaccine, the vaccine can act 
as a natural infection. The duration of protection 
from vaccines to strengthen the body's immunity 
against dengue virus is ranging from 5-6 years after 
administration of vaccination. (5) 
 
Current status of Dengvaxia vaccine 
developement 
The developmental status of the Dengvaxia 
vaccine test is interesting to continue to follow. 
While undergoing the 3rd phase clinical trial, 
Sanofi Pasteur stated that he did not collect blood 
samples used to determine the serostatus (had had 
previous dengue infection or not) before the 
vaccination process was carried out. Collection of 
blood data for all participants was only carried out 
at the 13th month (1 month after the 3rd vaccine 
dose was given). The assay method is used to 
recognize antibodies with a non-structural code of 
dengue protein (NS1) where the patient's status can 
still be known even though he has received 
previous vaccinations. This is because the NS1 
protein code for Dengvaxia is a protein code from 
the Yellow Fever vaccine.(6)  
 
Dengue vaccine Dengvaxia 
Dengvaxia vaccines are known to be widely 
accepted and can induce balanced immunity to all 
four serotypes. Based on this, the tetravalent CYD-
TDV dengue vaccine is known to be produced 
using a live attenuated flavivirus-17D vaccine and 
a yellow fever virus (YF-17D) strain as its 
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backbone. The CYD-TDV contained four YM-
17D chimeric viruses which gave rise to prM and 
E proteins from each of the 4 dengue serotypes. 
The dengvaxia vaccine was developed by OraVax 
for 10 years through preclinical testing to clinical 
trials, but this development did not continue until 
Acambis Inc. come to continue. The same thing 
happened, the development did not go as expected, 
until in 2005 Sanofi Pasteur bought the company. 
Furthermore, Sanofi Pasteur carried out a massive 
development and research on dengue vaccines 
which eventually could be patented under the trade 
name Dengvaxia.(7)  
In 2015, several countries such as Brazil, EL 
Savador, Mexico, and the Philippines, Dengvaxia 
vaccine was received and had security data. 
Indonesia through the RI POM agency issued a 
marketing permit on August 31, 2016 with 
indications as preventive for dengue cases caused 
by dengue serotypes 1,2,3 and 4 and given to 
individuals aged between 9-16 years, and with 
individual conditions they live in endemic areas.(8)  
The CYD-TDV vaccine is available in the 
form of a single dose vial injection or multi dose (5 
dose) vial. This vaccine product is stored in frozen 
form which can then be reconstituted if it is to be 
used. In the use for single dose purposes, it can be 
reconstituted with 0.4% NaCl solution, whereas for 
multi dose purposes it can be reconstituted with 
0.9% NaCl. Then after the preparation has been 
reconstituted, then 0.5 mL of the dose can be taken 
and given by injecting via the subcutaneous route 
(SC). While for the remaining solution can be put 
into the syringe for single dose administration or 
stored in a vial for multi dose administration. It is 
important to know that the CYD-TDV vaccine 
does not contain adjuvants or preservative 
ingredients and has a shelf-life of 36 months when 
stored at a temperature of 2 oC - 8 oC. This causes 
when the vaccine has been reconstituted with a 
compatible solvent, when the vaccine has not been 
used it must be stored at a temperature between 2 
oC - 8 oC and protected from sunlight or UV light. 
The WHO policy is related to multi-dose after 
reconstitution and there is a dose left in the vial, so 
the leftover part should be discarded within 6 hours 
of reconstitution or at the end of the vaccination 
session, depending on which one is first.(5)  
 
Dengue vaccine candidate TDV 
TDV vaccine (Takeda’s Dengue Vaccine 
Tetravalen) is a vaccine made as a candidate for 
another vaccine for dengue virus. This vaccine is 
made from the original DENV-2-PDK-53 vaccine 
that has been attenuated by the addition of 
mutations in NS3. TDV vaccine has been reported 
as a candidate for a safe and tolerable vaccine 
based on phase 1 and 2 clinical trials. There are 
three chimeric viruses, namely TDV-1, TDV-3, 
and TDV-4 which aim to replace PRM and E genes 
from DENV-1 , DENV-3, or DENV-4 to TDV-2. 
At present, TDV vaccines are still in phase 3 
clinical trial stages which are expected to be 
completed by the end of 2021.(3)  
 
Dengue vaccine candidate LAV Delta 30 
This type of vaccine has been developed by 
the National Institute of Health (NIH) which has 
specific characteristics with the elimination of 30 
contiguous nucleotides (Δ 30) and subsequently 
inserted into domain II from the tip of 3 'NTR RNA 
genomic. Removal (Δ 30) aims to weaken viruses 
DEN-1, -3, and -4. Furthermore, Butantan Institute 
licensed the Delta 30 LAV vaccine and changed its 
name to TV003. Phase 1 and 2 clinical trial results 
showed good safety and immunogenicity results 
with seroconversion rates starting at 50% (DENV-
2) to 100% (DENV-1, -3, and -4) after single dose 
administration. However, the presence of viruses in 
the blood is still detected in vaccinated individuals 
using TV003. Similar to the TDV vaccine, this 
vaccine is also still in the phase 3 clinical trial 
phase which is expected to be completed by 2022. 
(3)  
 
Dengue vaccine involving DNA technology 
The more sophisticated technology in this 
modern era, becomes an opportunity to design and 
develop new dengue vaccines as a preventive 
measure against dengue virus. This vaccine is still 
under development and pre-clinical testing and is 
still awaiting its safety data and effectiveness. 
Vaccine involving DNA technology has 
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recombinant subunits that require heterologous 
expression systems such as vectors, plasmid DNA, 
virus-like particles that only express PRM and 
protein E, or only reveal ED III from all four 
serotypes.(3)  
 
AGE OF GIVING DENGUE VACCINE  
Based on research data, currently dengue 
vaccines can be given starting at the age of 9 years 
or older in several countries in the world. A dengue 
vaccine (CYD-TDV) has a high effectiveness on 
all serotypes of dengue when given before 
exposure and its effectiveness increases with age. 
Based on seropositive values in children, overall 
vaccine effectiveness increased with age, ie 35.9% 
(95% CI: -7.6, 69.3) for children aged ≤5 years, 
65.6% (95 % CI: 40.3, 84.2) for ages 6-8 years, 
73.4% (95% CI: 62.6, 82.1) for ages 9-11 years, 
and 80.6% (95% CI: 72,9, 87.3) for ages 12 years 
or older.(9) 
Table 1. Estimated Levels of Effectiveness of 
Vaccines (EV%) Through Basic Immunity Status 
and Age Group CYD14 dan CYD15.  
According to the World Health Oragnization 
(WHO), CYD-TDV is a viral vaccine that is 
prophylactic. The dengue vaccine is given by 
injection of 0.5 mL 3 times with a range of 
administration for 6 months from each vaccination 
time. Early indications (licenses) for administering 
this vaccine are efforts to prevent dengue illnes by 
dengue virus serotypes 1,2,3 and 4 in individuals 
aged 9-45 years or 9-60 years who live in endemic 
areas. Meanwhile, for 9-year-olds, safety data is 
needed and for children aged 2-5 years the security 
data is still in phase III clinical trial stage.(5) 
Doctor Ari Prayitno, Sp.A (K) said that 
dengue vaccine can be started at any time since 
children aged 9-16 years. In addition, he also 
explained that vaccination after infection with 
dengue is still recommended. This is because, 
when a person (child) is infected with dengue it is 
usually only infected by one type of serotype from 
DENV and rarely is it directly infected by 4 
serotypes at once. This then raises the perception 
that by giving vaccinations containing 4 serotypes 
at once, the child's immunity will be formed to be 
immune to other serotypes that have not infected 
the child. In addition, giving vaccines to 
individuals who have had previous dengue 
infection can be beneficial to prevent the risk of 
more severe or severe dengue infection (dengue 
shock by secondary infection from other 
serotypes.(10) 
The data that is owned by the NRAs is in 
harmony with what was conveyed by doctor Ari 
Prayitno, Sp.A (K). Although there is no 
correlation that can be used as a link during age 
grouping in the effectiveness test, a phase 2 clinical 
trial shows that seropositive baseline is associated 
with increased age and stability of titres after 
vaccination. The results of this effectiveness are 
shown between the ages of 9-16 years and this 
condition is predicted to be similar to the adult 
population in endemic areas.(5) 
 
USE AND SECURITY OF DENGUE 
VACCINE 
Research on vaccination, especially dengue 
vaccines, is very important for an endemic country. 
It is known that 4 dengue virus serotypes (DEN-1, 
DEN-2, DEN-3, DEN-4) revolve globally and the 
most reported annually is in endemic countries. 
WHO states that dengue vaccine can only be used 
in areas that are very endemic to dengue fever. In 
addition, to obtain the best population level 
strategy, WHO recommends looking at 
seroprevalence as a basis for consideration of the 
efficacy and safety level of protection in 
seropositive individuals. These considerations are 
based on the SAGE (Strategic Advisory Group of 
Experts). Seroprevalence is a level of seropositivity 
to a particular pathogen in a population. 
Mathematically, the calculation to determine the 
optimal seroprevalence is obtained in the age group 
targeted for vaccination which is around 70% or 
more, if it is in the range of 50% - 70% it is still 
acceptable but with lower effectiveness. This is 
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different from seroprevalence below 50%, WHO 
does not provide recommendations for vaccination. 
Because in addition to its low effectiveness, it can 
also cause a potential long-term risk for the 
occurrence of severe dengue fever in seronegative 
individuals.(5) 
The safety of the dengue vaccine needs to be 
considered during the use process. This is related 
to adverse reactions that can occur in the CYD 
TDV vaccine. for example, the reaction of the 
adverse effects of this vaccine is local and 
systemic. Systemic reactions occurred at 66.5% in 
CYD-TDV recipients and 59% in placebo 
recipients. In general, systemic reactions that occur 
are like headache (> 50%), malaise (> 40%), and 
myalgia (> 40%). Whereas symptoms of fever 
occur at 5% in the age group 18 - 60 years and 16% 
in the age group 9-17 years. Local reactions 
occurred at 49.6% in the group receiving CYD-
TDV and by 38.5% in the group receiving placebo. 
In general, local reactions that occur are pain of 
45.2% felt by the age group 18-60 years and 49.2% 
in the age group 9-17 years. In general, the 
outcome of serious adverse reactions to date still 
has no relevant data found.(5)  
The provision of the Dengvaxia vaccine as a 
preventive measure against dengue virus has 
attracted the attention of the Indonesian Food and 
Drug Administration to evaluate the safety of this 
vaccine. The results of re-evaluation of the 
Indonesian Food and Drug Administration on the 
Dengvaxia vaccine are divided into two parts, 
namely individuals who have never had dengue 
virus infection (seronegative) will be at high risk of 
experiencing severe dengue and at risk of being 
hospitalized higher than seronegative individuals 
only given a placebo. In addition, it is also known 
that the administration of Dengvaxia vaccine in 
children aged> 9 years with seronegative has lower 
efficacy compared to individuals who have had 
dengue infection (seropositive). Reaffirmed by the 
Indonesian Food and Drug Administration, the 
efficacy of the Dengvaxia vaccine is better when 
given to seropositive individuals ranging in age 
from 9-16 years.(8) 
The Indonesian Food and Drug 
Administration has decided several things after re-
evaluating as above, namely 1) the Dengvaxia 
vaccine can be used as a preventive measure 
against the risk of dengue fever occurrence and 
severity in children aged 9 to 16 years and had 
previously experienced infection dengue virus 
(seropositive) and 2) Dengvaxia vaccine is 
prohibited from using seronegative individuals. 
Even though there is currently no data on the side 
effects of the Dengvaxia vaccine, in order to 
prevent undesirable events, the Indonesian Food 
and Drug Administration has appealed to all 
relevant parties including Peer Health 
Professionals to prioritize patient safety in the 
administration of vaccines as well as the 
Indonesian Food and Drug Administration. to PT. 
Aventis Pharma continues to monitor the use of the 
Dengvaxia vaccine in the territory of Indonesia. (8)  
 
VACCINATION PROGRAMMES 
The use of the CYD-TDV vaccine has a 
significant impact on dengue disease at the age of> 
9 years. Based on comparisons of several 
mathematical models, the vaccination program 
using the CYD-TDV vaccine is known to reduce 
symptoms and hospital care due to dengue illness 
by 10% - 30% over a 30-year period. Based on data 
for cost effectiveness, One DALY tried to calculate 
the total cost incurred in dengue cases was 2000 US 
dollars. Therefore, in overcoming this, efforts are 
made to prevent dengue or preventive measures 
and look for alternative vaccines that can be used 
in at least some endemic countries, as well as cost 
effectiveness predictions for dengue cases. The 
results obtained are the total costs incurred for a 
full vaccination per person is around 15-40 US 
dollars or when using a societal perspective the 
total cost incurred for a full vaccination per person 
is less than 100-150 US dollars. However, this data 
is only a comparative model and cannot be used as 
a basis for making decisions based on specific 
analysis in each country. (5) 
 
HUMAN CONTRAINDICATION TO 
DENGUE VACCINE 
Contraindications to drug use also occur in 
vaccine administration. According to WHO 
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(2016), there are several contraindications to the 
use of dengue vaccine, namely 1) an individual 
who has a history of allergies to components 
contained in dengue vaccines or with other 
vaccines containing the same components as 
dengue vaccines; 2) individuals with impaired 
innate immunity or immune deficiencies obtained 
to mediate immune cells; 3) individuals with 
symptoms (symptomatic) of HIV infection or 
asymptomatic HIV infection accompanied by 
evidence of failure of immune function; 4) 
pregnant or lactating women; and administration of 
vaccines should be delayed in patients with 
moderate to severe febrile conditions or acute 
disease.(5)  
 
DISCUSSION 
The emergence of information about 
vaccines for dengue virus is now increasingly 
widespread. According to doctor Hunied Kautsar, 
the national immunization program for dengue 
vaccine is still a pro and contra, which is the reason 
that this vaccine cannot be included in the national 
immunization program. The unavailability of 
dengue vaccine in the national immunization 
program causes the administration to be limited, so 
clinicians (doctors) need to pay attention to the 
recommendations that have been submitted by the 
RI POM and WHO that the Dengvaxia dengue 
vaccine is only indicated for individuals aged 9 to 
16 years with seropositive status and living in the 
area endemic for dengue. 
 
CONCLUSION 
Dengue virus can affect anyone, especially 
individuals or groups in endemic areas. Every 
element of society needs to be alert to contracting 
this virus. Currently several vaccines are being 
developed as prophylaxis to reduce the severity of 
dengue virus infection. Until this period, only one 
vaccine has been allowed to be released by WHO, 
the Dengvaxia vaccine and has been accepted in 
several countries in Europe and Asia. Other 
vaccine candidates are still in the pre-clinical trial 
phase and phase 3 clinical trial. The use of the 
Dengvaxia vaccine is still limited by WHO, which 
is only at the age of 9-16 years and is in the 
endemic area of dengue fever. Likewise in 
Indonesia, the Indonesian Food and Drug 
Administration also adopted recommendations 
from the WHO to limit the use of the Dengvaxia 
vaccine. Based on serovalence, the safety and 
effectiveness of using Dengvaxia vaccine is better 
when given to seropositive individuals compared 
to seronegative individuals or in other words, 
individuals who have previously had dengue 
infection are then vaccinated, so the effectiveness 
and safety are higher compared to individuals who 
have never experienced infection previous dengue. 
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